(Q34395006)

1 August 2017

1 reference

title

Medical therapy of pulmonary hypertension. The prostacyclins (English)

1 reference

1 August 2017

Galié N

1

1 reference

1 August 2017

Manes A

series ordinal

2

1 reference

1 August 2017

Branzi A

series ordinal

3

1 reference

1 August 2017

publication date

1 September 2001

1 reference

Clinics in Chest Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

22

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

529-37, x

1 reference

A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Decreased arterial wall prostaglandin production in neonatal calves with severe chronic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Continuous intravenous epoprostenol therapy for pulmonary hypertension in Gaucher's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Vasodilator therapy for primary pulmonary hypertension in children

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Role of prostacyclin in the treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Pulmonary hypertension--beyond vasodilator therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Role of pharmacologic tests in the treatment of primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Pulmonary prostacyclin synthase overexpression in transgenic mice protects against development of hypoxic pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Interactions between endothelial mediators

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Treatment of primary pulmonary hypertension intravenous epoprostenol (prostacyclin)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Protective effect of beraprost sodium, a stable prostacyclin analogue, in development of monocrotaline-induced pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Orally active prostacyclin analogue in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Inhaled iloprost to treat severe pulmonary hypertension. An uncontrolled trial. German PPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Aerosolized Prostacyclin and Iloprost in Severe Pulmonary Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheep

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Prostacyclin-induced acute pulmonary vasodilation in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Short-term hemodynamic effect of a new oral PGI2 analogue, beraprost, in primary and secondary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Positive inotropic and chronotropic effects of beraprost sodium, a stable analogue of prostacyclin, in isolated guinea pig myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Pharmacodynamic profile of prostacyclin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Prostacyclin and prostaglandin E1 for severe idiopathic pulmonary artery hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

Vascular protection: A novel nonangiogenic cardiovascular role for vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-5231%2805%2970289-6

7 January 2021

10.1016/S0272-5231(05)70289-6

Identifiers

DOI

1 reference

1 August 2017

1 reference